Scarica l'app Stockscreener
0.392
2.51%
-0.0101
Dopo l'orario di chiusura:
.40
0.008
+2.04%
Bioaffinity Technologies Inc Borsa (BIAF) Ultime notizie
Enterprise value to revenue forward of bioAffinity Technologies, Inc. – NASDAQ:BIAF - TradingView
BioAffinity Technologies Closes $4 Million Private Placement - Moomoo
bioAffinity Technologies closes $4M private placement - Investing.com
bioAffinity Technologies closes $4 million private placement of pre-funded warrants priced at $0.47 - Bitget
WallachBeth Capital Announces Closing of bioAffinity Technologies $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules - PR Newswire
bioAffinity Technologies closes $4M private placement By Investing.com - Investing.com Nigeria
bioAffinity Technologies Announces Closing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules - Yahoo Finance
bioAffinity Technologies prices $4M private placement offering - Investing.com
WallachBeth Capital Announces bioAffinity Technologies Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules - Barchart.com
bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules - Business Wire
bioAffinity Technologies to Add Mexican Patent to its CyPath Lung Technology IP - Medical Product Outsourcing
bioAffinity Technologies Inc (BIAF) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Enterprise value to EBITDA forward of bioAffinity Technologies, Inc. – NASDAQ:BIAFW - TradingView
Form 8K bioAffinity Technologies Inc For: 7 August By Investing.com - Investing.com Nigeria
bioAffinity Technologies earnings beat by $1.46, revenue fell short of estimates - Investing.com Canada
BioAffinity Technologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
bioAffinity Technologies, Inc. Q2 2026: Revenue $1.51M, EPS $(0.64) — 10-Q Summary - TradingView
BIAF: Strong CyPath® Lung growth drives Q2 2026, but liquidity concerns persist amid ongoing losses - TradingView
Price to sales forward of bioAffinity Technologies, Inc. – NASDAQ:BIAFW - TradingView
BIAF: Q2 2026 saw 216% CyPath Lung test growth and 19% revenue increase, with improved net loss - TradingView
bioAffinity Technologies reports Q2 2026 revenue $1.51M, net loss $3.37M, cash $2.43M - TradingView
Price to earnings forward of bioAffinity Technologies, Inc. – NASDAQ:BIAFW - TradingView
Press Release: BioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath(R) Lung - Moomoo
bioAffinity Technologies Inc (BIAF) Stock News Today - TradingKey
bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung - Yahoo Finance
bioAffinity Technologies Faces Nasdaq Delisting Risk After Notice - The Globe and Mail
bioAffinity Technologies and Pictor Apply Flow Cytometry, Proteomic Analysis to Gauge Lung Health - Photonics Spectra
bioAffinity Technologies Inc (BIAF) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung - BioSpace
bioAffinity Technologies Inc (BIAF) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
bioAffinity Technologies Inc (BIAF) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
bioAffinity, Pictor Collaborate on Asthma and COPD Tests - respiratory-therapy.com
bioAffinity Technologies Highlights CyPath Lung Clinical Framework - TipRanks
bioAffinity Technologies publishes clinical framework to integrate CyPath® Lung into nodule evaluation - TradingView
bioAffinity Technologies, Inc. Revenue Breakdown – BOATS:BIAFW - TradingView
bioAffinity Technologies, Inc. Revenue Breakdown – BOATS:BIAF - TradingView
bioAffinity Technologies Inc (BIAF) Balance Sheet - TradingKey
bioAffinity Technologies Inc (BIAF) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BIAF Q3 2025 Earnings: EPS Misses Estimates; No Revenue ReportedEPS Estimate Trend - po-news-eg.net
bioAffinity Technologies, Inc. (BIAF) stock price, news, quote and history - Yahoo Finance UK
Top QumulusAI (QMLS) Competitors 2026 - MarketBeat
bioAffinity Technologies Q3 2025 Earnings: EPS Misses Estimates Amid Ongoing Research FocusSaaS Earnings Trends - dars.gov.et
bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity's Diagnostics for Asthma and COPD | Newswise - Newswise
bioAffinity Technologies Inc (BIAF) Income Statement - TradingKey
bioAffinity Technologies Inc (BIAF) Cash Flow - TradingKey
BIAF Stock Gains As CyPath Sales Surge 146% In Q1 - Stocktwits
BIAF|bioAffinity Technologies Inc|Price:0.663|Chg%:-0.005 - TradingKey
bioAffinity Technologies Inc (BIAF) Valuation: PE, PB & Fair Value Analysis - TradingKey
BIAF vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now? - The Globe and Mail
What's Driving bioAffinity Technologies' Recent Surge - Kavout | AI
BioAffinity Technologies and Pictor, Inc. Partner to Develop and Commercialize bioAffinity's Diagnostics for Asthma and COPD - marketscreener.com
bioAffinity Technologies, Inc. (BIAF) Stock Price, News, Quote & History - Yahoo! Finance Canada
bioAffinity and Pictor partner on diagnostics for asthma and COPD - Yahoo Finance
BioAffinity Technologies Inc (BIAF) Fundamental & Financial Data - Stocktwits
bioAffinity Technologies and Pictor Partner to Develop High-Throughput, Cost-Effective Diagnostics for Asthma and COPD – Minichart - Minichart
bioAffinity and Pictor partner on lung inflammation diagnostics - TipRanks
bioAffinity partners with Pictor on asthma, COPD tests By Investing.com - Investing.com South Africa
1.64%
0.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):